Erratum: Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer Harboring BRAF Class 3 Mutations

JCO Precision Oncology 2026

View at publisher
Authors: Alessandro Di Federico, Stefania Angelicola, Mariateresa Frascino, Irene Siracusa, Beatrice Bisanti, Francesca Ruzzi, Maria Sofia Semprini, Hugo R. de Jonge, Andrea De Giglio, Francesca Sperandi, Stefano Brocchi, Barbara Melotti
+7 more Francesca Giunchi, Elisa Gruppioni, Annalisa Altimari, Pier‐Luigi Lollini, Andrea Ardizzoni, Arianna Palladini, Francesco Gelsomino
DOI: 10.1200/po-26-00034
Cited by: 0

Fields of Study & Subjects

Lung Cancer Treatments and Mutations HER2/EGFR in Cancer Research Lung Cancer Diagnosis and Treatment

Publication details

Journal / source
JCO Precision Oncology
Volume
10
Issue
1
Pages
e2600034–e2600034
Publication date
1 January 2026
Language
EN